Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia

To see complete record on, please visit this link

Id: NCT05128162

Organisation Name: TRYP Therapeutics

Overal Status: Not yet recruiting

Start Date: March 2022

Last Update: November 19, 2021

Lead Sponsor: TRYP Therapeutics

Brief Summary: The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating TRP-8802 therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral TRP-8802 in concert with psychotherapy to treat chronic pain symptoms in patients with FM.

  • Fibromyalgia

Total execution time in seconds: 0.30139994621277